Arcus Biosciences price to sales ratio RCUS

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 20.2×
8-year median: 12.5×
Against its 8-year history: 59th; percentile: 0 is its lowest day, 100 its highest
8-year range: 2.8× to 117×
Peer median: 2.0×

Arcus Biosciences' price to sales ratio is 20.2× as of Oct 23, 2026.

That is above its 8-year median of 12.5×, close to the middle of its last 8 years.

Over that time it ranged from 2.8× in Apr 2025 to 117× in Feb 2020.

The median for 10 large drugmakers of a similar size is 2.0×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.2×	8.5×	33.0×
2025	10.4×	2.8×	11.7×
2024	5.3×	5.1×	15.2×
2023	11.9×	3.1×	13.9×
2022	3.5×	3.4×	69.3×
2021	75.1×	19.2×	88.2×
2020	21.7×	16.9×	117×
2019	71.7×	31.6×	71.7×

Against its peers

Companies in Drug Manufacturers - General nearest Arcus Biosciences' size, closest first, today.

Company	Price to sales ratio
RCUSArcus Biosciences	20.2×
PBHPrestige Consumer Healthcare	2.0×
HRMYHarmony Biosciences	2.2×
NRIXNurix Therapeutics	3.9×
ANIPANI Pharmaceuticals	1.7×
PAHCPhibro Animal Health	1.0×
OGNOrganon	0.6×
LQDALiquidia	8.5×
ANABAnaptysbio	n/m
PCRXPacira BioSciences	1.9×
ARQTArcutis Biotherapeutics	8.5×
Peer median	2.0×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Arcus Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.